Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 18, 2018 09:41 ET | Source: Paratek Pharmaceuticals

Paratek Announces Pricing of Public Offering of Common Stock

BOSTON, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
January 17, 2018 16:06 ET | Source: Paratek Pharmaceuticals

Paratek Announces Public Offering of Common Stock

BOSTON, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
January 03, 2018 07:00 ET | Source: Paratek Pharmaceuticals

Paratek Provides Update on Pipeline Progress

Rolling NDA submission underway for omadacycline in pneumonia and skin infectionsOmadacycline Phase 2 program underway for the treatment of urinary tract infections$5 million milestone payment earned...
December 01, 2017 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
November 08, 2017 07:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018

Granted QIDP designation for uncomplicated Urinary Tract Infections (uUTI) by the FDA Highlighted prelaunch activities during Investor Day presentations in October BOSTON, Nov. 08, 2017 (GLOBE...
November 01, 2017 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
October 24, 2017 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017

BOSTON, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
October 06, 2017 08:01 ET | Source: Paratek Pharmaceuticals

Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria

SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- New microbiology data from Paratek Pharmaceuticals (Nasdaq:PRTK) show that its well-tolerated, once-daily, oral and IV, broad-spectrum investigational...
October 06, 2017 08:00 ET | Source: Paratek Pharmaceuticals

Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions

- No dosing adjustment anticipated in these special populations SAN DIEGO, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals (Nasdaq:PRTK) announced the results of three sub-analyses from...
October 02, 2017 16:01 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...